

EMAA Project – Medication Abortion Survey

Washington, DC, February 13, 2023 -- These are the findings of an Ipsos poll conducted between February 9-10, 2023 on behalf of EMAA Project. For this survey, a sample of 1,005 adults age 18+ from the continental U.S., Alaska, and Hawaii was interviewed online in English. The poll has a credibility interval of plus or minus 3.8 percentage points for all respondents.

For full results, please refer to the following annotated questionnaire:

Full Annotated Questionnaire

1. Are you registered to vote at your current address, or not?

	Total	Democrats	Republicans	Independents
Yes, registered to vote at my current address	79%	87%	86%	73%
No, not registered to vote at my current address	19%	12%	12%	26%
Not sure	2%	1%	2%	1%

2. In June 2022, the U.S. Supreme Court overturned Roe vs. Wade, eliminating the national constitutional right to abortion. Do you [RANDOMLY ROTATE 'agree' and 'disagree'] agree or disagree with this decision?

	Total	Democrats	Republicans	Independents
Strongly agree	19%	5%	35%	17%
Somewhat agree	14%	10%	21%	12%
Somewhat disagree	12%	10%	14%	14%
Strongly disagree	44%	70%	20%	42%
Not sure	11%	5%	9%	16%
Total Agree	33%	15%	56%	28%
Total Disagree	56%	80%	35%	56%

Continued on Page 2





PUBLIC POLL FINDINGS AND METHODOLOGY

3. Medication abortion was approved by the Food and Drug Administration (FDA) more than 20 years ago. Please tell us how much you [RANDOMLY ROTATE 'agree' and 'disagree'] agree or disagree with the following statement:

	Total	Democrats	Republicans	Independents
Strongly agree	42%	68%	23%	33%
Somewhat agree	23%	16%	26%	34%
Somewhat disagree	8%	4%	10%	10%
Strongly disagree	13%	5%	25%	3%
Not sure	14%	7%	16%	20%
Total Agree	65%	84%	49%	67%
Total Disagree	21%	9%	35%	13%

Medication abortion should remain legal in the United States.

4. There is currently a case before a federal judge in Texas asking the court to overturn the FDA's approval of medication abortion. Please tell us how much you [RANDOMLY ROTATE 'agree' and 'disagree'] agree or disagree with the following statement:

The federal judge should override the FDA's approval of medication abortion, banning medication abortion in the United States.

	Total	Democrats	Republicans	Independents
Strongly agree	14%	9%	24%	7%
Somewhat agree	15%	8%	20%	21%
Somewhat disagree	13%	10%	16%	13%
Strongly disagree	40%	65%	20%	35%
Not sure	18%	8%	20%	24%
Total Agree	29%	17%	44%	28%
Total Disagree	53%	75%	35%	48%

Continued on Page 3

Contact: Annaleise Lohr Director, US, Public Affairs, Ipsos Email: annaleise.lohr@ipsos.com





5. Here is some additional information on medication abortion:

Medication abortion is safe, effective, and was approved by the FDA in 2000, with some restrictions on distribution. In 2021, the FDA reviewed the evidence and now allows prescriptions to be picked up at a pharmacy or mailed to patients, similar to other medications. It is used for more than 50% of abortions in the U.S. The medication is also used for incomplete miscarriages to help patients avoid infection, infertility, or even death.

Please tell us how much you [RANDOMLY ROTATE 'agree' and 'disagree'] agree or disagree with the following statements:

	Total	Democrats	Republicans	Independents
Strongly agree	43%	69%	23%	38%
Somewhat agree	23%	18%	26%	27%
Somewhat disagree	8%	4%	13%	7%
Strongly disagree	12%	3%	23%	8%
Not sure	14%	6%	15%	20%
Total Agree	66%	87%	49%	65%
Total Disagree	20%	7%	36%	15%

a. A federal judge should allow medication abortion to remain legal.

	Total	Democrats	Republicans	Independents
Strongly agree	41%	67%	21%	34%
Somewhat agree	22%	16%	24%	26%
Somewhat disagree	12%	6%	18%	14%
Strongly disagree	12%	4%	21%	9%
Not sure	14%	7%	16%	17%
Total Agree	62%	83%	45%	60%
Total Disagree	24%	10%	39%	23%

b. The courts banning medication abortion would harm women and their families.





About the Study

These are some of the findings of an Ipsos poll conducted between February 9-10, 2023 on behalf of EMAA Project. For this survey, a sample of 1,005 adults age 18+ from the continental U.S., Alaska, and Hawaii was interviewed online in English. The sample includes 420 Democrats, 391 Republicans, and 117 independents.

The sample for this study was randomly drawn from <u>lpsos' online panel</u>, partner online panel sources, and "<u>river</u>" sampling and does not rely on a population frame in the traditional sense. Ipsos uses fixed sample targets, unique to each study, in drawing a sample. After a sample has been obtained from the lpsos panel, lpsos calibrates respondent characteristics to be representative of the U.S. Population using standard procedures such as raking-ratio adjustments. The source of these population targets is U.S. Census 2021 American Community Survey data. The sample drawn for this study reflects fixed sample targets on demographics. Post-hoc weights were made to the population characteristics on gender, age, race/ethnicity, region, education and political party affiliation.

Statistical margins of error are not applicable to online non-probability polls. All sample surveys and polls may be subject to other sources of error, including, but not limited to coverage error and measurement error. Where figures do not sum to 100, this is due to the effects of rounding. The precision of Ipsos online polls is measured using a credibility interval. In this case, the poll has a credibility interval of plus or minus 3.8 percentage points for all respondents. Ipsos calculates a design effect (DEFF) for each study based on the variation of the weights, following the formula of Kish (1965). This study had a credibility interval=+/-5.3 percentage points).

The poll also has a credibility interval of plus or minus 5.9 percentage points for Democrats, plus or minus 6.1 percentage points for Republicans, and plus or minus 11.1 percentage points for independents.

For more information on this news release, please contact:

Chris Jackson Senior Vice President, US Public Affairs <u>chris.jackson@ipsos.com</u>

Annaleise Lohr Director, US Public Affairs annaleise.lohr@ipsos.com

2020 K Street, NW, Suite 410 Washington DC 20006 +1 202 463-7300 Contact: Annaleise Lohr Director, US, Public Affairs, Ipsos Email: annaleise.lohr@ipsos.com





About Ipsos

Ipsos is one of the largest market research and polling companies globally, operating in 90 markets and employing over 18,000 people.

Our passionately curious research professionals, analysts and scientists have built unique multi-specialist capabilities that provide true understanding and powerful insights into the actions, opinions and motivations of citizens, consumers, patients, customers or employees. Our 75 solutions are based on primary data from our surveys, social media monitoring, and qualitative or observational techniques.

Founded in France in 1975, Ipsos is listed on the Euronext Paris since July 1st, 1999. The company is part of the SBF 120 and the Mid-60 index and is eligible for the Deferred Settlement Service (SRD).

ISIN code FR0000073298, Reuters ISOS.PA, Bloomberg IPS:FP www.ipsos.com

